132 related articles for article (PubMed ID: 35018778)
1. Beyond Isocitrate Dehydrogenase Mutations: Emerging Mechanisms for the Accumulation of the Oncometabolite 2-Hydroxyglutarate.
Peng S; Chen H; Chen L; Yang G; Liu J; Cheng X; Tang Y
Chem Res Toxicol; 2022 Feb; 35(2):115-124. PubMed ID: 35018778
[TBL] [Abstract][Full Text] [Related]
2. D-2-Hydroxyglutarate in Glioma Biology.
Chou FJ; Liu Y; Lang F; Yang C
Cells; 2021 Sep; 10(9):. PubMed ID: 34571995
[TBL] [Abstract][Full Text] [Related]
3. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Xu W; Yang H; Liu Y; Yang Y; Wang P; Kim SH; Ito S; Yang C; Wang P; Xiao MT; Liu LX; Jiang WQ; Liu J; Zhang JY; Wang B; Frye S; Zhang Y; Xu YH; Lei QY; Guan KL; Zhao SM; Xiong Y
Cancer Cell; 2011 Jan; 19(1):17-30. PubMed ID: 21251613
[TBL] [Abstract][Full Text] [Related]
4. Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates.
Ye D; Guan KL; Xiong Y
Trends Cancer; 2018 Feb; 4(2):151-165. PubMed ID: 29458964
[TBL] [Abstract][Full Text] [Related]
5. Degradation of D-2-hydroxyglutarate in the presence of isocitrate dehydrogenase mutations.
Berger RS; Ellmann L; Reinders J; Kreutz M; Stempfl T; Oefner PJ; Dettmer K
Sci Rep; 2019 May; 9(1):7436. PubMed ID: 31092874
[TBL] [Abstract][Full Text] [Related]
6. Oncometabolite d-2-hydroxyglutarate impairs α-ketoglutarate dehydrogenase and contractile function in rodent heart.
Karlstaedt A; Zhang X; Vitrac H; Harmancey R; Vasquez H; Wang JH; Goodell MA; Taegtmeyer H
Proc Natl Acad Sci U S A; 2016 Sep; 113(37):10436-41. PubMed ID: 27582470
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
[TBL] [Abstract][Full Text] [Related]
8. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
9. Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Evans B; Griner E;
Elife; 2015 Jul; 4():e07420. PubMed ID: 26231040
[TBL] [Abstract][Full Text] [Related]
10. To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.
Bhavya B; Anand CR; Madhusoodanan UK; Rajalakshmi P; Krishnakumar K; Easwer HV; Deepti AN; Gopala S
Cell Mol Neurobiol; 2020 Jan; 40(1):53-63. PubMed ID: 31485826
[TBL] [Abstract][Full Text] [Related]
11. 2-Hydoxyglutarate: D/Riving Pathology in gLiomaS.
Wahl DR; Venneti S
Brain Pathol; 2015 Nov; 25(6):760-8. PubMed ID: 26526944
[TBL] [Abstract][Full Text] [Related]
12. Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma.
Miyake K; Baba Y; Ishimoto T; Hiyoshi Y; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Ogata Y; Nagayama M; Silsirivanit A; Kobayashi D; Araki N; Baba H
Med Oncol; 2018 Nov; 36(1):11. PubMed ID: 30506321
[TBL] [Abstract][Full Text] [Related]
13. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.
Wang P; Wu J; Ma S; Zhang L; Yao J; Hoadley KA; Wilkerson MD; Perou CM; Guan KL; Ye D; Xiong Y
Cell Rep; 2015 Dec; 13(11):2353-2361. PubMed ID: 26686626
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
[TBL] [Abstract][Full Text] [Related]
15. Acidic pH Is a Metabolic Switch for 2-Hydroxyglutarate Generation and Signaling.
Nadtochiy SM; Schafer X; Fu D; Nehrke K; Munger J; Brookes PS
J Biol Chem; 2016 Sep; 291(38):20188-97. PubMed ID: 27510037
[TBL] [Abstract][Full Text] [Related]
16. D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced
Li T; Cox CD; Ozer BH; Nguyen NT; Nguyen HN; Lai TJ; Li S; Liu F; Kornblum HI; Liau LM; Nghiemphu PL; Cloughesy TF; Lai A
Mol Cancer Res; 2018 Jun; 16(6):947-960. PubMed ID: 29545476
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate.
Yuan BF
Adv Exp Med Biol; 2021; 1280():161-172. PubMed ID: 33791981
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.
van Lith SA; Navis AC; Lenting K; Verrijp K; Schepens JT; Hendriks WJ; Schubert NA; Venselaar H; Wevers RA; van Rooij A; Wesseling P; Molenaar RJ; van Noorden CJ; Pusch S; Tops B; Leenders WP
Sci Rep; 2016 Jul; 6():30486. PubMed ID: 27460417
[TBL] [Abstract][Full Text] [Related]
19. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
20. In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors.
Salamanca-Cardona L; Shah H; Poot AJ; Correa FM; Di Gialleonardo V; Lui H; Miloushev VZ; Granlund KL; Tee SS; Cross JR; Thompson CB; Keshari KR
Cell Metab; 2017 Dec; 26(6):830-841.e3. PubMed ID: 29056515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]